An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DNYMH, CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.

Антитело anti-CEA моноклональное, обозначенное 806.077, из murine начала полезно для диагноза и терапии рака. Комплементарность антитела обусловливая зоны имеет following последовательности: тяжелая цепь CDR1 DNYMH, CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD ы; и светлое цепное CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. Антитело опционно humanized и может быть in the form of конъюгат с или энзимом, such as карбоксипептидаза, или чо-co-stimulatory молекула such as внеклеточный домен людского B7.1.